Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Inovio Pharmaceuticals, Inc. (INO)
Price$1.43Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65,343 | $217,756 | $832,010 | $10.3M | $1.8M | $7.4M | $4.1M | $30.5M | $42.2M | $35.4M | $40.6M | $10.5M | $13.5M | $4.1M | $9.8M | $6.1M | $9.1M |
| Research & development | $54.2M | $75.6M | $86.7M | $187.7M | $249.2M | $94.2M | $88.0M | $95.3M | $98.6M | $88.7M | $57.8M | $34.1M | $21.4M | $18.0M | $20.0M | $13.3M | $9.4M |
| Operating expenses | $86.9M | $112.6M | $144.8M | $277.8M | $303.0M | $131.5M | $115.2M | $124.6M | $125.9M | $111.6M | $74.9M | $50.0M | $33.0M | $27.6M | $31.4M | $25.4M | $23.1M |
| Operating income | −$86.8M | −$112.4M | −$143.9M | −$267.6M | −$301.2M | −$124.1M | −$111.1M | −$94.1M | −$83.6M | −$76.2M | −$34.3M | −$39.5M | −$19.5M | −$23.5M | −$21.6M | −$19.2M | −$14.0M |
| Operating margin | −132,871.32% | −51,616.91% | −17,300.28% | −2,607.35% | −16,972.34% | −1,674.25% | −2,702.10% | −308.68% | −198.11% | −215.55% | −84.50% | −377.71% | −145.12% | −570.42% | −220.91% | −312.79% | −153.04% |
| EBITDA | −$85.4M | −$110.6M | −$141.2M | −$263.4M | −$297.7M | −$120.5M | −$106.4M | −$89.1M | −$80.2M | −$73.1M | −$32.4M | −$37.9M | −$17.4M | −$21.5M | −$19.6M | −$17.1M | −$12.3M |
| EBITDA margin | −130,701.36% | −50,812.27% | −16,967.70% | −2,566.88% | −16,771.72% | −1,625.86% | −2,588.66% | −292.29% | −189.90% | −206.82% | −79.77% | −362.70% | −129.54% | −521.98% | −200.37% | −278.48% | −134.66% |
| Net income | −$84.9M | −$107.3M | −$135.1M | −$279.8M | −$303.7M | −$166.4M | −$119.4M | −$97.0M | −$88.2M | −$73.7M | −$29.2M | −$36.1M | −$66.0M | −$19.7M | −$15.3M | −$17.6M | −$24.4M |
| Net profit margin | −130,000.00% | −49,254.27% | −16,239.87% | −2,726.67% | −17,109.87% | −2,245.39% | −2,902.75% | −318.12% | −208.92% | −208.49% | −71.94% | −345.44% | −490.29% | −477.56% | −155.72% | −286.65% | −267.67% |
| Basic EPSper basic share | -$1.81 | -$3.95 | -$6.09 | -$14.07 | -$17.45 | -$154.14 | -$174.31 | -$151.26 | -$155.58 | -$145.50 | -$61.95 | -$87.88 | -$206.00 | -$83.55 | -$69.15 | -$97.96 | -$190.16 |
| Diluted EPSper diluted share | -$1.81 | -$3.95 | -$6.09 | -$14.07 | -$17.45 | -$154.14 | -$174.31 | -$151.26 | -$157.02 | -$145.50 | -$63.39 | -$92.20 | -$206.00 | -$83.55 | -$69.15 | -$97.96 | -$190.16 |
Owners
Reported shareholders
10.27%of listed shares
FMR LLC8.45M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
FMR LLC | 10.27%8.45M shares |
Jupiter Topco LLC | 6.28%5.17M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.43%3.65M shares |
Boxer Capital Management, LLC | 3.46%2.84M shares |
ADAR1 Capital Management, LLC | 2.60%2.14M shares |
D. E. Shaw & Co., Inc. | 1.64%1.35M shares |
TWO SIGMA INVESTMENTS, LP | 1.51%1.24M shares |
Eversept Partners, LP | 1.26%1.04M shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.97%802.75K shares |
MILLENNIUM MANAGEMENT LLC | 0.97%796.11K shares |
BlackRock, Inc. | 0.95%779.06K shares |
VANGUARD FIDUCIARY TRUST CO | 0.58%480.77K shares |
Caption Management, LLC | 0.58%478.95K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.44%361.34K shares |
STATE STREET CORP | 0.41%336.61K shares |
GSA CAPITAL PARTNERS LLP | 0.32%265.01K shares |
UBS Group AG | 0.32%262.32K shares |
Quadrature Capital Ltd | 0.31%258.93K shares |
CITADEL ADVISORS LLC | 0.29%241.78K shares |
NORTHERN TRUST CORP | 0.21%174.39K shares |
Percentages use 82.34M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data